In conjunction with emerging epidemiological data supporting a relatively high prevalence of disruptive, impulse-control, and conduct disorders, the small amount of data regarding effective treatments highlights the clinical need for additional research.
Empirically supported treatment options for impulse-control disorders currently are limited, because only select disorders have been studied across multiple trials. New research is needed to confirm possible treatment options and identify effective psychotherapeutic and pharmacological treatment alternatives.
• Grant JE. Impulse control disorders: a clinician’s guide to understanding and treating behavioral addictions. New York, NY: W. W. Norton & Company; 2008.
• Grant JE, Kim SW. Stop me because I can’t stop myself: taking control of impulsive behavior. New York, NY: McGraw- Hill; 2003.
• American Academy of Child and Adolescent Psychiatry. Conduct disorder resource center. http://www.aacap.org/AACAP/FamiliesandYouth/ResourceCenters/ConductDisor....
Drug Brand Names
Atomoxetine • Strattera Methylphenidate • Ritalin
Carbamazepine • Tegretol Molindone • Moban
Citalopram • Celexa Naltrexone • ReVia
Clonazepam • Klonopin Olanzapine • Zyprexa
Clonidine • Catapres Oxcarbazepine • Trileptal
D-amphetamine • Dexedrine Quetiapine • Seroquel
Divalproex sodium • Depakote Risperidone • Risperdal
Escitalopram • Lexapro Sertraline • Zoloft
Fluoxetine • Prozac Sodium valproate • Depacon
Guanfacine • Intuniv Thioridazine • Mellaril
Haloperidol • Haldol Topiramate • Topamax
Levetiracetam • Keppra Valproic acid • Depakote
Lithium • Eskalith, Lithobid
Dr. Grant receives grant or research support from Brainsway, Forest Pharmaceuticals, and Roche Pharmaceuticals. Mr. Leppink reports no financial relationship with any company whose products are mentioned in this article or with competing products.